The value of immunohistochemistry on paraffin wax embedded tissue sections in the differentiation of small lymphocytic and mantle cell lymphomas

N Singh, D H Wright

Abstract
Aims—To determine whether immunohistochemistry applied to paraffin wax embedded biopsy tissue can be used to distinguish between B-small lymphocytic lymphoma (B-SLL) and mantle cell lymphoma (MCL).

Methods—Formalin fixed, paraffin wax embedded tissue blocks of 12 cases of B-SLL and 12 cases of MCL were retrieved from the files of the Department of Pathology, Southampton University Hospitals Trust. Following antigen retrieval, where appropriate, sections were stained for CD3, CD5, CD20, CD23, CD43, Cyclin D, PGP9.5, and MIB1 using a streptavidin-biotin complex technique.

Results—CD20 stained the neoplastic cells of B-SLL and MCL, and CD3 labelled the reactive T cells in these tumours. In B-SLL, the T cells were generally dispersed among the tumour cells, whereas in MCL they often formed bands around tumour cell nodules. CD5 could be detected on T cells, following antigen retrieval. The level of expression on B cells of B-SLL and MCL was generally too low to allow detection in paraffin wax embedded tissues. CD23 stained B-SLL but not MCL. However, it could be detected in only five of the 12 cases of B-SLL. CD43 could be detected in most cases of B-SLL and MCL. It is not, therefore, of value in distinguishing between these tumours. It will, however, help in the differentiation of B-SLL and MCL from other low grade B cell lymphomas, such as follicle centre cell and marginal zone lymphomas. Cyclin D was expressed in all of the MCL but in none of the B-SLL. PGP9.5 showed reactivity in most cases of MCL and much weaker reactivity in B-SLL. The proliferation indexes of MCL were generally higher than those of B-SLL, as measured by MIB1 labelling. Both tumours, however, showed a wide range of values and considerable overlap.

Conclusion—Staining for Cyclin D is the most reliable immunohistochemical means of differentiating between B-SLL and MCL. High levels of PGP9.5, expressed in MCL, may be related to the degradation of Cyclin D by the ubiquitin pathway.

Keywords: B-small lymphocytic lymphoma; mantle cell lymphoma; Cyclin D.

Mantle cell lymphoma (MCL)1-3 has been widely accepted as the preferred term for the lymphoma previously designated as centrocytic lymphoma (Kiel classification),1 intermediately1-4 or poorly differentiated lymphocytic (Rappaport),5 small cleaved follicular centre cell (Lukes and Collins),6 small cleaved cell (Working Formulation),7 and mantle zone lymphoma.8 A proportion of MCL have blastic features and may mimic lymphoblastic lymphoma in routinely processed tissue sections.9 At the other end of the morphological spectrum, MCL may resemble small lymphocytic lymphoma (B-SLL/B-CLL), as the tumour cell nuclei in both of these lymphomas may be round or cleaved.2 It has also been our experience. Whereas there are well defined morphological characteristics that separate B-SLL and MCL,11 these may not be apparent in all biopsy specimens, depending on, amongst other factors, the size of the specimen and the quality of fixation. The distinction between these two entities is of importance, as MCL usually follows a more aggressive course1-12 and treatment needs to be modified accordingly. A number of studies have shown the value of flow cytometry13 or immunohistochemistry on frozen sections14-15 in separating these lymphomas. The pathologist with only a fixed, paraffin wax embedded biopsy specimen, however, does not have the option of using these techniques. We have, therefore, studied the discriminatory value of a panel of antibodies reactive in fixed, paraffin wax embedded...
tissues for the identification and separation of B-SLL and MCL.

Methods

Using standard morphological criteria, 12 cases of B-SLL and 12 cases of MCL were selected from the files of the Department of Pathology, Southampton University Hospitals Trust. Some of these cases had been biopsied locally and others had been referred from elsewhere. Brief clinical details of these patients are given in table 1. All biopsy specimens had been fixed in formal saline. For morphological evaluation, all biopsy specimens were stained with haematoxylin and eosin, Giemsa stain, periodic acid Schiff, and for reticulin using the Gordon and Sweet method.

Immunohistochemistry was done using a streptavidin-biotin-complex technique, with antigen retrieval when appropriate. Sections were incubated with the primary antiserum at 4°C overnight. Details of section pretreatment, antibodies used and their specificities are given in table 2. Microwave pretreatment was done in 0.01 sodium citrate buffer, pH 6.0, at 560 W for 25 minutes. Sections were evaluated by both authors. Labelling indexes were determined by one author (NS) on sections labelled with MIB1 by counting 10 high power fields using an eyepiece graticule.

Results

The 12 cases of B-SLL showed the characteristic histological features of this lymphoma. Para-immunoblasts were usually evident, either singly (fig 1) or aggregated into proliferation centres (fig 2), although in a few cases they were absent from much of the tumour (fig 3). In two cases, the para-immunoblasts formed the majority of the tumour cells, consistent with the 'tumour forming subtype' of B-SLL.15 The MCL cases showed a range of morphologies from uniform small lymphoid cells (fig 4) to more pleomorphic tumours, with irregular nuclei (fig 5). Most cases showed a vaguely nodular growth pattern. Naked germinal centres were present at the centre of occasional nodules, giving the appearance of a mantle zone lymphoma. Characteristic histiocytes, with eosinophilic cytoplasm, were seen in all cases (fig 4).

The immunohistochemical findings are shown in table 3. Staining for CD3 and CD20 did not discriminate between tumour cells of B-SLL and MCL, but did identify different distributions of the reactive T cells in the two tumour types. In B-SLL, reactive T cells were irregularly scattered amongst the tumour cells (fig 6), whereas in MCL they often appeared as...
defined bands of cells between the tumour cell nodules (figs 7 and 8). CD5 is expressed by both B-SLL and MCL cells, but in the paraffin wax embedded tissues used in the present study the expression was detected in only a minority of cases and was weak. This contrasted with the strong expression on reactive T cells. CD23 is expressed on B-SLL but not MCL cells. However, in the present study, expression was seen in only five cases of B-SLL, the staining being more pronounced in para-immunoblasts than small lymphocytes (fig 9). No cases of MCL stained for CD23, although labelling of a dispersed network of dendritic reticulum cells was seen in these tumours (fig 10). Cyclin D was expressed by all of the MCL in this series but by none of the B-SLL. The reactivity was seen in the nuclei of the tumour cells and varied in any one tumour from negative to strong (figs 11 and 12). All but one MCL strongly expressed PGP9.5 (fig 13). Seven of the B-SLL stained positively with this antibody, but this was usually much weaker than that seen in MCL. The labelling index with MIB1 varied widely in both tumours, the mean index being slightly higher for MCL than for B-SLL (figs 14 and 15).

We found no difference in the morphology or immunoreactivity of MCL occurring in lymph nodes and the two cases that had intestinal tumours.
Differentiation of small lymphocytic and mantle cell lymphomas

**Discussion**

Mantle cell lymphoma has been recognised as a distinct entity in recent years. The Kiel group originally thought that it was of follicle centre cell origin, hence their use of the term 'centrocytic lymphoma'. In the Working Formulation it was designated diffuse, small cleaved cell lymphoma and shown to have a prognosis intermediate between low and high grade lymphomas. Because of its more aggressive behaviour, it should be separated from low grade lymphomas and possibly treated differently. Morphological criteria on which this separation can be based are well defined but, in our experience, the separation of B-SLL from MCL can be difficult. The tumour cells of B-SLL are typically round lymphocytes, whereas the cells of MCL are angulated or cleaved. However, the tumour cells of B-SLL may show angulated nuclei and those of MCL may be rounded. The presence of para-immunoblasts is probably the most reliable way of separating B-SLL from MCL but they are not always easy to find and they may be mimicked by residual centroblasts, histiocytes and dendritic reticulum cell nuclei, more so in haematoxylin and eosin than in Giemsa stained preparations. It was for this reason that we looked at the feasibility of using immunohisto-
proliferation centres. The Figure 14 magnification x120). ahigh Mshoingu labtraright)howralymphoemdedinretrieval. antigen themexpressed onorfCD5marcmarsigniatignsparsatluespicelofed(orgalBmagnificationcelluararevlmriglass." CD23, CD23, a low affinity receptor for IgE, is expressed on the cells of B-SLL but not on chemical markers, applicable to paraffin wax embedded tissues, to make this distinction.

CD20 is expressed on mature B cells and CD3 is expressed on T cells. These two antibodies would not, therefore, be expected to distinguish between B-SLL and MCL at the cellular level. They do, however, highlight the architectural differences between these two neoplasms. B-SLL usually shows a scattering of T cells throughout the tumour, whereas in MCL they form bands between the nodules of lymphoma cells. CD5 is expressed on the cells of both B-SLL and MCL and may be used to separate them from follicle centre cell and marginal zone (MALT) lymphomas on frozen sections. Antigen retrieval techniques permit the detection of CD5 in paraffin wax embedded tissue but, as the present study shows, the level of expression of this antigen on B cells precludes reliable identification, in contrast to T cells which are labelled. It remains to be seen whether signal enhancement techniques will overcome this problem. In contrast, CD43 can be demonstrated on the cells of B-SLL and MCL, in almost all cases, following microwave antigen retrieval. This antigen will not discriminate between B-SLL and MCL but will separate them from follicle centre cell lymphomas and marginal zone lymphomas.

CD23, a low affinity receptor for IgE, is expressed on the cells of B-SLL but not on those of MCL and may be used with frozen section immunohistochemistry or flow cytometry to separate these two neoplasms. In this study, we found expression of CD23 on only five of 12 cases of B-SLL, precluding its use as a routine marker in paraffin wax sections. Again, it remains to be seen whether other methods of antigen retrieval or signal enhancement techniques will overcome this problem.

Mantle cell lymphoma is characterised by a translocation between the Cyclin D1 gene on chromosome 11 and the immunoglobulin heavy chain gene on chromosome 142-25 in about 70% of cases. This translocation results in the overexpression of Cyclin D1 in the nuclei of the tumour cells of MCL,26 which is also seen in cases of MCL without detectable molecular evidence of t(11;14). With one exception, expression of Cyclin D1 has not been seen in B-SLL. It has also been recorded rarely in hairy cell leukaemia and plasmacytoma.28 Our studies confirm Cyclin D1 as the most reliable marker for the distinction between B-SLL and MCL. A monoclonal antibody directed against Cyclin D1 is now available and, in our experience, works as well as the polyclonal antibody used in this study.

Antibodies directed against protein gene product 9.5 (PGP9.5) detect the Li isoenzyme of ubiquitin carboxy-terminal hydrolase and are used as markers of neuronal differentiation. Langlois et al.29 discovered that, after microwave heating in citrate buffer, lymphoid follicles also stained strongly with this antibody. These authors subsequently tested a range of lymphomas using this technique but found no relation between type or grade of lymphoma and staining of tumour cells. Western blots carried out on brain and tonsil extracts, using the polyclonal antibody, showed a band of greater molecular weight than PGP9.5 in the tonsil extract. Langlois et al.2 concluding that this additional band might represent other isoenzymes of ubiquitin carboxy-terminal hydrolase that can be found in other tissues, including lymphoma cell lines. The one example of MCL (centrocytic lymphoma) included in their study showed strong staining with PGP9.5. In our study we found strong staining for PGP9.5 in 11 of the 12 cases of MCL. Seven of the 12 cases of B-SLL also showed reactivity but generally with much weaker staining. Cyclin is degraded by the ubiquitin pathway and it may be that the stronger expression of PGP9.5 in MCL is related to the overexpression of Cyclin D1 in these tumours. From a practical point of view, it is unlikely that polyclonal antibodies directed against PGP9.5 will be of value in the identification of MCL. However, antibodies directed against other isoenzymes of ubiquitin carboxy-terminal hydrolase might be worthy of further investigation.

We are indebted to Dr Kevin Gatter, Professor Nancy Harris and Professor Rodney Thompson for the gift of antibodies. We thank Lorraine West and Julie Williams for performing the immunohistochemistry and Julie Foster for typing the manuscript.

Differentiation of small lymphocytic and mantle cell lymphomas


